Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development. It also markets medical devices, including the CoSense End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns; and NeoPip T-piece resuscitator and related consumables, which deliver consistent pre-set inspiratory pressure and positive end-expiratory pressures, as well as temperature probes, scales, surgical tables, and patient surfaces. In addition, the company offers Serenz, a handheld device that delivers non-inhaled carbon dioxide topically to the nasal mucosa. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444
Debt
Debt-to-Equity RatioN/A
Current Ratio8.14
Quick Ratio8.14
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.45 million
Price / Sales42.27
Cash FlowN/A
Price / CashN/A
Book Value$1.38 per share
Price / Book2.25
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-15,660,000.00
Net MarginsN/A
Return on Equity-54.36%
Return on Assets-40.91%
Miscellaneous
Employees18
Outstanding Shares19,770,000
Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions
What is Soleno Therapeutics' stock symbol?
Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?
Shares of Soleno Therapeutics reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Soleno Therapeutics' earnings last quarter?
Soleno Therapeutics Inc (NASDAQ:SLNO) released its quarterly earnings results on Wednesday, May, 16th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.08. View Soleno Therapeutics' Earnings History.
When is Soleno Therapeutics' next earnings date?
What price target have analysts set for SLNO?
3 Wall Street analysts have issued 1 year price objectives for Soleno Therapeutics' stock. Their forecasts range from $4.00 to $14.00. On average, they anticipate Soleno Therapeutics' share price to reach $7.3333 in the next twelve months. View Analyst Ratings for Soleno Therapeutics.
Who are some of Soleno Therapeutics' key competitors?
Some companies that are related to Soleno Therapeutics include BioLife Solutions (BLFS), Fonar (FONR), Helius Medical Technologies (HSDT), Second Sight Medical Products (EYES), Zynex Inc. common stock (ZYXI), BioSig Technologies (BSGM), Edap Tms (EDAP), Viveve Medical (VIVE), Semler Scientific (SMLR), IRIDEX (IRIX), Stereotaxis (STXS), Digirad (DRAD), Aradigm (ARDM), Dynatronics (DYNT) and Nexeon Medsystems (NXNN).
Who are Soleno Therapeutics' key executives?
Soleno Therapeutics' management team includes the folowing people:
- Dr. Anish Bhatnagar, Pres, CEO, Principal Financial & Accounting Officer and Director (Age 48)
- Mr. Anthony Wondka, Sr. VP of R&D (Age 56)
- Mr. David D. O'Toole, Consultant (Age 59)
- Mr. Jonathan R. Wolter, Interim Chief Financial Officer (Age 68)
- Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.
Has Soleno Therapeutics been receiving favorable news coverage?
Media stories about SLNO stock have trended somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Soleno Therapeutics earned a daily sentiment score of 0.21 on Accern's scale. They also gave headlines about the company an impact score of 45.63 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Soleno Therapeutics?
Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soleno Therapeutics' stock price today?
One share of SLNO stock can currently be purchased for approximately $3.10.
How big of a company is Soleno Therapeutics?
Soleno Therapeutics has a market capitalization of $45.78 million and generates $1.45 million in revenue each year. Soleno Therapeutics employs 18 workers across the globe.
How can I contact Soleno Therapeutics?
Soleno Therapeutics' mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]
MarketBeat Community Rating for Soleno Therapeutics (SLNO)
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
